Hong Kong · Sponsored
Triple-Negative Breast Cancer: Insights from ASCO 2024
This content is sponsored. It is intended for healthcare professionals only.
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterised by the absence of oestrogen receptors (ER), progesterone receptors, and human epidermal growth factor receptor 2 (HER2) amplification.1,2 Representing about 10–15% of all breast cancer cases, TNBC is associated with poor prognosis and limited treatment options.2 Recent research findings presented at the 2024 American Society of Clinical Oncology (ASCO) meeting provided updates on new advances in the treatment of TNBC.
